MVision AI Receives FDA Clearance for Guideline-Based Segmentation Software
MVision AI announces that it receives 510(k) clearance from the FDA for guideline-based, AI-powered software for automatic segmentation for radiotherapy.
Precision, consistency, and reliability play an important role in radiotherapy for cancer treatment. Robust, guideline-compliant auto-segmentation brings quality and standardization to the clinical workflow.
MVision’s guideline-based segmentation software integrates seamlessly with hospital systems to provide consistent and reliable contours of critical structures - and improve the clinical workflow.
MVision AI primarily operates with cloud-based solutions. However, the software is also available on local servers. To guarantee the most secure and optimal user experience, MVision is HIPAA and GDPR compliant.
Mahmudul Hasan, CEO and founder of MVision AI states:
“We are truly excited to bring MVision’s AI-powered guideline-based segmentation (GBS™) solution to the US market. Our GBS™ solution is widely used in the EU and UK hospitals. These clinics have reported significant workflow efficiency gains, improved consistency, and standardization for contouring.”
About MVision AI
MVision AI provides the highest quality of contours for your radiation oncology workflow needs.
MVision was founded in 2017, providing many hospitals in EU and EMEA countries with innovative software solutions. With the 510(k) clearance, MVision takes another step towards offering the highest quality auto segmentation service globally.
To learn more, visit: https://www.mvision.ai/
Angela Werner
MVision AI
angela.werner@mvision.ai
Visit us on social media:
Facebook
Twitter
LinkedIn
Other
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
